Use of novel psychoactive substances by inpatients on general adult psychiatric wards: A retrospective case note review

First published: 30/03/2019 | Last updated: May 20th, 2019

Dr Daniel Mogford

Consultant Psychiatrist

Dr Daniel Mogford is a recently appointed ST4 in General Adult Psychiatry, currently placed in NHS Fife. He has broad interests including substance misuse and the relationships that exist between physical and mental health. He is active in local clinical teaching programs. Daniel completed Core Psychiatry Training in the South East of Scotland, having moved from Australia in 2012. Prior to relocating, he gained his primary medical qualification as a graduate entrant at Flinders University in Adelaide and has a Bachelor of Arts (History) from the University of New South Wales.



Objectives

Non-illicit alternatives to controlled drugs, known as Novel Psychoactive Substances (NPS), have recently risen to prominence. They are readily available, with uncertain pharmacology and no widely available assay. Given that psychiatric patients are at risk of comorbid substance abuse, we hypothesized that NPS use would be present in the psychiatric population, and sought to determine its prevalence and investigate the characteristics of those who use these drugs with a retrospective review of discharge letters.

Setting

General adult inpatient wards of a psychiatric hospital in a Scottish city.

Participants

All adult inpatients (18-65) discharged from general psychiatric wards between 1/7/14 and 31/12/14. Of the 483 admissions identified, 46 were admissions for maintenance ECT and were excluded. Of the remaining 437 admissions, 49 discharge letters were unobtainable, leaving 388 admissions to analyze.

Primary outcome measure

The mention, or lack thereof, of NPS use in discharge letters was our planned primary outcome measure and was also the primary outcome measure we used in our analysis.

Results  

NPS use was identified in 22.2% of admissions, contributing to psychiatric symptoms in 59.3%. In comparison to non-users, NPS users were younger (p<0.01), male, and more likely to have a forensic history ((p<0.001) for both). The diagnosis of drug-induced psychosis was significantly more likely in NPS users (p<0.001, odds ratio (OR) 18.7, 95% confidence intervals (CI) 8.1-43.0) and the diagnosis of depression was significantly less likely (p<0.005, OR 0.133, CI 0.031-0.558). Use of cannabis was significantly more likely in NPS users (p<0.001, OR 4.2, CI 2.5-7.1), as was substitute opiate prescribing (p<0.001, OR 3.7, CI 1.8-7.4).

Conclusions  

NPS use was prevalent amongst young, male psychiatric inpatients, in particular those with drug induced psychosis and often occured alongside illicit drug use.

Resources



Download the presentation

Download the full presentation here



Listen to the presentation audio

Audio of this presentation is available on Soundcloud below:

Alternatively, please visit the Sound Cloud website to listen

Dr Daniel Mogford


 

Covid-19

As an organisation, we continue to function during the developing pandemic.

We are following all government and Charity Commission guidance in respect of staff and reporting issues.

Our funding schemes remain open and we are continuing to programme our conferences planned for November 2020.